First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05054348. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion, and Dose-Randomization Study of IO 108 as Monotherapy and in Combination With Either Pembrolizumab or Cemiplimab in Adult Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of the clinical trial is to learn about safety, tolerability and preliminary efficacy of IO-108 as monotherapy or in combination with a PD-1 inhibitor in patients with advanced, metastatic solid tumors, and to find a dose of IO-108 that is safe and efficacious to be tested in patients with various solid tumors.
Study identification
- NCT ID
- NCT05054348
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Interventions
- IO-108 Biological
- IO-108 + pembrolizumab combination therapy Biological
- IO-108 + cemiplimab combination therapy Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 29, 2021
- Primary completion
- Apr 28, 2024
- Completion
- May 30, 2024
- Last update posted
- Jun 3, 2024
2021 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates, PC-HOPE (140) (USOR SITE) | Tucson | Arizona | 85711 | — |
| Beverly HIlls Cancer Center (129) | Beverly Hills | California | 90211 | — |
| Rocky Mountain Cancer Centers, LLP (141) (USOR SITE) | Lone Tree | Colorado | 80124 | — |
| University of Florida (125) | Gainesville | Florida | 32611 | — |
| Florida Cancer Specialists (134) | Lake Mary | Florida | 32746 | — |
| Memorial Cancer Institute (146) | Pembroke Pines | Florida | 33021 | — |
| Florida Cancer Specialists & Research Institute (103) | Sarasota | Florida | 34232 | — |
| Hematology Oncology (136) | Stuart | Florida | 34952 | — |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center (123) | Indianapolis | Indiana | 46202 | — |
| Maryland Oncology Hematology, PA (145) (USOR SITE) | Columbia | Maryland | 21044 | — |
| Karmanos Cancer Institute (126) | Detroit | Michigan | 48201 | — |
| St. Vincent - Frontier Cancer Center (135) | Billings | Montana | 59102 | — |
| NYU Langone Health (131) | New York | New York | 10016 | — |
| Carolina BioOncology (102) | Huntsville | North Carolina | 28078 | — |
| Gabrail Cancer Center (128) | Canton | Ohio | 44718 | — |
| Oncology Hematology Care Clinical Trials, LLC (144) (USOR SITE) | Cincinnati | Ohio | 45242 | — |
| Providence Cancer Institute (104) | Portland | Oregon | 97213 | — |
| UPMC Hillman Cancer Center (105) | Pittsburgh | Pennsylvania | 15209 | — |
| Texas Oncology - Austin (142) (USOR SITE) | Austin | Texas | 78705 | — |
| Texas Oncology - Baylor Charles A. (143) (USOR SITE) | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center (101) | Houston | Texas | 77030 | — |
| Oncology Consultants, P.A. (138) | Houston | Texas | 77030 | — |
| NEXT Oncology-Virginia (121) | Fairfax | Virginia | 22031 | — |
| Swedish Cancer Institute (147) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05054348, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05054348 live on ClinicalTrials.gov.